🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. INEBILIZUMAB, 10 mL (nominal) solution containing 20 mM histidine/histidine hydrochloride, 70 mM sodium chloride, 106 mM (4% [w/v]) trehalose dihydrate, and 0.01% (w/v) polysorbate 80

    Elan Pharma International

    Immunoglobulin G4-related disease (IgG4-RD)

    phase 3 small molecule active

    1 trial

  2. INFLIXIMAB , MYCOPHENOLIC ACID , SALINE, ETOPOSIDE , CARBOPLATIN , PEMETREXED , IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN , PACLITAXEL

    AstraZeneca AB

    Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III)

    phase 3 small molecule active

    1 trial

  3. INFLIXIMAB, DS-8201a, AZD6738, MYCOPHENOLATE MOFETIL, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Patients with non-small cell lung cancer (NSCLC).

    phase 3 small molecule active

    1 trial

  4. INFLIXIMAB, FOLINIC ACID, IMFINZI 50 mg/mL concentrate for solution for infusion., DOCETAXEL, PLACEBO, OXALIPLATIN, FLUOROURACIL, MYCOPHENOLATE MOFETIL

    AstraZeneca AB

    Histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition).

    phase 3 small molecule active

    1 trial

  5. INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., BEVACIZUMAB, MYCOPHENOLATE MOFETIL, DEXTROSE BP, SODIUM CHLORIDE

    AstraZeneca AB

    Histologically or cytologically confirmed Locoregional Hepatocellular Carcinoma (HCC) and successfully completed curative therapy (resection or ablation)

    phase 3 small molecule active

    1 trial

  6. INFLIXIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Rilvegostomig, MYCOPHENOLATE MOFETIL

    AstraZeneca AB

    Lung Cancer

    phase 3 small molecule active

    1 trial

  7. INFLIXIMAB, MYCOPHENOLATE MOFETIL, Placebo, BEVACIZUMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., BEVACIZUMAB

    AstraZeneca AB

    Locoregional Hepatocellular Carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  8. INFLIXIMAB, Rilvegostomig, MYCOPHENOLATE MOFETIL, IMJUDO 20 mg/ml concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion., ATEZOLIZUMAB , BEVACIZUMAB

    AstraZeneca AB

    Advanced Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  9. INFLIXIMAB, SODIUM CHLORIDE, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, IMJUDO 20 mg/ml concentrate for solution for infusion., DEXTROSE BP

    AstraZeneca AB

    Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC)

    phase 3 small molecule active

    1 trial

  10. INZ-701

    BioMarin Pharmaceutical Australia Pty Ltd

    Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency

    phase 3 small molecule active

    2 trials

  11. INZ-701

    Lacuna Pharma Pty Ltd

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

    phase 3 small molecule active

    1 trial

  12. INZ-701, INZ-701

    Lacuna Pharma Pty Ltd

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

    phase 3 small molecule active

    1 trial

  13. IO102-IO103

    IO Biotech

    Metastatic Melanoma

    phase 3 small molecule active

    1 trial

  14. ION 682884, ION 682884

    IONIS PHARMACEUTICALS INC

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

    phase 3 small molecule active

    1 trial

  15. ION363, ION363, Artificial Cerebrospinal Fluid (aCSF) for Injection, 5.0 mL (Placebo)

    IONIS PHARMACEUTICALS INC

    Amyotrophic Lateral Sclerosis with Fused in Sarcoma mutations

    phase 3 small molecule active

    1 trial

  16. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  17. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  18. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical hemolytic uremic syndrome

    phase 3 small molecule active

    1 trial

  19. IPTACOPAN HYDROCHLORIDE

    Novartis Pharmaceuticals

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  20. IPTACOPAN, LNP023

    Novartis Pharmaceuticals

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  21. IRBESARTAN, DAPAGLIFLOZIN, Sparsentan_DF3, Sparsentan_DF2

    Travere Therapeutics

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  22. IRINOTECAN , FLUOROURACIL , OXALIPLATIN , CALCIUM LEVOFOLINATE , CALCIUM FOLINATE

    Pari Pharma GmbH

    Middle or low locally advanced resectable rectal carcinoma

    phase 3 small molecule active

    1 trial

  23. IRINOTECAN HYDROCHLORIDE, CAPECITABINE, OXALIPLATIN, CAPECITABINE, CALCIUM FOLINATE, FLUOROURACIL

    The George Institute

    Rectum cancer

    phase 3 small molecule active

    1 trial

  24. IRINOTECAN, REGORAFENIB, Stivarga 40 mg film-coated tablets

    The George Institute

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources